Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and other GLP-1 receptor agonists have delivered significant weight loss results for millions of patients, with FDA trials showing average reductions of 15–22% body weight. However, recent patient reports and social media discussions have raised questions about whether these medications can trigger or worsen depression. PlexusDx breaks down what the clinical evidence actually shows and how personalized genetic testing can help identify patients who may face higher mood-related risks.
What Does the Clinical Evidence Say About Semaglutide and Mood?
Major clinical trials of semaglutide (Wegovy, Ozempic) did not identify depression as a primary adverse event. The STEP trials, which followed over 4,500 participants, reported depression in fewer than 2% of semaglutide users—a rate similar to placebo groups. However, these trials were not specifically designed to measure subtle mood changes, and longer-term observational data continues to emerge.
The FDA added a safety review in 2024 to examine potential neuropsychiatric effects across the entire GLP-1 class, including semaglutide and tirzepatide. This does not mean causation has been proven; rather, the agency is investigating whether a signal exists in real-world use. Mental health screening questionnaires were not standard in original pivotal trials, so milder mood shifts may not have been systematically captured.
Several mechanisms could explain mood changes in some patients: rapid weight loss itself triggers hormonal shifts that influence serotonin and dopamine pathways; appetite suppression can reduce nutrient intake if dietary choices are not balanced; and some patients experience social or identity challenges as their body composition changes. These factors are distinct from the medication directly targeting mood-related brain circuits.
Why Some Patients Report Mood Changes on GLP-1 Therapy
Semaglutide works by stimulating GLP-1 receptors throughout the body and brain. While the medication's primary target in the brain is appetite and blood sugar control, GLP-1 receptors are also present in regions that modulate stress response, reward processing, and emotional regulation. Whether activation of these receptors produces mood changes likely depends on individual genetic and biochemical differences.
Nutritional deficiencies are a practical concern during rapid weight loss. Patients who reduce food intake dramatically without planning nutrient-dense meals may develop insufficient B vitamins, iron, omega-3 fatty acids, or amino acids needed for neurotransmitter synthesis. Low amino acid availability can reduce serotonin production, potentially contributing to depressed mood independent of the medication itself.
Psychological factors also matter: weight loss is emotionally complex. Some patients experience positive mood shifts from improved health and confidence. Others report unexpected grief, identity confusion, or loss of food as an emotional coping mechanism. These responses are real and important to address with mental health support, not dismissed as the medication's fault.
How Genetic Testing Can Identify Your Depression Risk Profile
PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic and mood-related pathways, including variants in serotonin signaling genes, dopamine regulation, and stress-response pathways. Key variants such as those in the serotonin transporter (5-HTT) and catechol-O-methyltransferase (COMT) genes influence how your brain processes neurotransmitters—and therefore how you may respond emotionally to rapid metabolic changes.
The test identifies whether you carry genetic predispositions that make you more sensitive to mood disruption during weight loss therapy. For example, some patients have genetic variants that reduce their capacity to synthesize serotonin efficiently; these individuals benefit from earlier nutritional counseling and closer mood monitoring. Others have variants that increase stress sensitivity, suggesting they may need more psychological support during treatment.
Armed with this genetic insight, PlexusDx clinicians can adjust your medication protocol, dosing schedule, and nutritional recommendations before depression-risk situations develop. The test costs $99 as an add-on after your first month of treatment, allowing you to start therapy while genetic results are being analyzed.
Safe Steps to Protect Your Mental Health While on Semaglutide
Monitor your mood actively from day one. Keep a simple mood journal noting energy level, sleep quality, motivation, and emotional tone three times per week. If you notice a decline that persists beyond two weeks, notify your PlexusDx clinician immediately rather than stopping medication on your own. Many mood shifts are temporary and resolve with dosing adjustments or nutritional support.
Prioritize nutrient-dense eating even during appetite suppression. Work with a registered dietitian who understands GLP-1 therapy to ensure adequate protein (0.7–1.0g per pound of goal body weight), omega-3 fatty acids, B vitamins, and minerals. Low nutrient intake is one of the most preventable causes of mood decline during weight loss.
Maintain or increase mental health support, not decrease it. If you have a history of depression, anxiety, or bipolar disorder, inform PlexusDx during your initial assessment. Genetic testing results can highlight whether you need concurrent therapy or mood monitoring. Exercise, social connection, and adequate sleep are proven mood stabilizers that work synergistically with medication.
PlexusDx Semaglutide Injection: Personalized Access and Support
PlexusDx Compounded Semaglutide Injection starts at $149 per month across all commitment tiers, with consistent pricing regardless of your dose level—because your dose may need to go up, but your price won't. The medication is compounded by licensed 503A pharmacies and shipped to all 50 states with no insurance requirement or membership fee. HSA and FSA accounts are accepted for additional savings.
Your treatment plan includes baseline mood assessment, regular check-in calls to monitor mental health alongside weight loss, and access to PlexusDx's clinical team. If you experience mood changes, the team can investigate nutritional gaps, adjust your semaglutide schedule, or recommend the Precision Peptide Genetic Test to understand your individual risk profile. Many patients who initially hesitated due to depression concerns have successfully completed therapy once they received proper monitoring and personalized guidance.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Did clinical trials prove that semaglutide causes depression?
No. The major STEP trials reported depression rates of 1–2% in semaglutide users, comparable to placebo groups. The FDA is conducting a safety review to examine real-world reports, but this is a precautionary investigation, not confirmation of causation.
What should I do if I feel depressed while taking semaglutide?
Contact PlexusDx or your prescriber immediately—do not stop the medication on your own. Your clinician will assess whether the mood change coincides with dosing, nutritional intake, sleep, or life stress. Often, a small dosing adjustment, dietary counseling, or mental health support resolves the issue.
How much does the Precision Peptide Genetic Test cost?
The test costs $99 as an add-on after your first month of treatment. It analyzes 14 pathways and 49 peptides to identify your individual genetic risk for mood and metabolic responses, helping PlexusDx clinicians customize your medication protocol and prevent depression-related complications before they start.
Can I take semaglutide if I already have depression or take antidepressants?
Yes, many patients with pre-existing depression use semaglutide successfully. However, inform PlexusDx during your assessment so the team can monitor you closely and coordinate care with your mental health provider.
Does the PlexusDx Precision Peptide Genetic Test predict depression risk on semaglutide?
Yes. The test identifies variants in serotonin, dopamine, and stress-response pathways that influence how your brain handles rapid metabolic changes during weight loss.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How GLP-1 Medications Affect Your Gut Health and Microbiome
Optimizing Your Journey: Is There a Best Time of Day to Take Semaglutide?